ChristopherTHagenstadMD

Oncology • Lawrenceville, GA

Physician

Join to view full profile

Dr. Hagenstad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hagenstad's full profile

Already have an account?

Office
631 Professional Dr
Ste 210
Lawrenceville, GA 30046
Phone+1 678-312-3235

Fax+1 678-312-2020

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1998 - 2001
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1998

Certifications & Licensure

GA State Medical License 2003 - 2025
NC State Medical License 2001 - 2004
VA State Medical License 1998 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012

Clinical Trials

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2

Publications & Presentations

PubMed

2 citations
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects wi...
Sara A. Hurvitz, Linda D. Bosserman, David Chan, Christopher T Hagenstad, Frederick C Kass
Springerplus. 2014-05-12
81 citations
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
Johanna C. Bendell, John Nemunaitis, Sasha Vukelja, Christopher Hagenstad, Luis T. Campos
Journal of Clinical Oncology. 2011-11-20
8 citations
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Sara A. Hurvitz, Heather Allen, Rebecca L. Moroose, David Chan, Christopher T Hagenstad
Clinical Breast Cancer. 2010-08-01